AHIMA develops QA resource kit

Two professional associations have partnered to create a resource kit that addresses healthcare organizations' need for quality assurance (QA) programs.

The absence of a QA program in EHR documentation processes can compromise patient care and safety, revenue cycle management and risk management, according to a release from the American Health Information Management Association (AHIMA) and the Association for Healthcare Documentation Integrity (AHDI).

To help healthcare organizations focus on the integrity of patient documentation, AHIMA and AHDI created a resource kit--Clinician-Created Documentation: Reinstating Quality Assurance Programs to Safeguard Patients and Providers--that provides the tools needed to implement a QA program.

The kit offers standards for measurement, reporting and documentation improvement that will help promote accuracy in patient records.

"Having a QA program is an essential component to ensuring patient safety," said AHIMA CEO Lynne Thomas Gordon, MBA, RHIA. "AHIMA and AHDI urge healthcare organizations to reinstate QA programs as part of a comprehensive plan that focuses on quality health information."

QA differs from clinical documentation improvement in that it facilitates accurate representation of a patient's clinical status that translates into coded data, while a QA program is the complete review of the narrative and demographic data to protect the patient, caregiver and the organization's document integrity, according to the organizations.

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.